Annual report pursuant to Section 13 and 15(d)

Balance Sheet Details

v3.3.1.900
Balance Sheet Details
12 Months Ended
Dec. 31, 2015
Balance Sheet Related Disclosures [Abstract]  
Balance Sheet Details
Balance Sheets Details
Accounts receivable
The following is a summary of activity in our allowance for doubtful accounts for the periods presented (in thousands):
 
 
December 31,
 
 
2015
 
2014
 
2013
Allowance - beginning of period
 
$
(428
)
 
$
(460
)
 
$
(150
)
Provision for bad debts
 

 
(11
)
 
(386
)
Recoveries from bad debts
 
7

 

 
76

Write-offs and other
 

 
43

 

Allowance - end of period
 
$
(421
)
 
$
(428
)
 
$
(460
)

Inventories
Inventories consisted of the following (in thousands): 
 
December 31,
 
2015
 
2014
Raw materials (1)
$
262

 
$
84

Work in process (2)

 
65

Finished goods
730

 
1,246

Total
$
992

 
$
1,395


(1)
Raw materials include active pharmaceutical ingredients and other raw materials.
(2)
Work-in-process and finished goods include third party manufacturing costs and labor and indirect costs we incur in the production process.
Property and Equipment, net
Property and equipment, net consisted of the following (in thousands): 
 
December 31,
 
2015
 
2014
Laboratory equipment
$
20,503

 
$
23,002

Leasehold improvements
10,369

 
9,773

Computer equipment and software
3,271

 
3,262

Office equipment and furniture
1,178

 
1,227

Construction in progress (1)
3

 
24

Property and equipment
35,324

 
37,288

Less: accumulated depreciation and amortization
(32,215
)
 
(31,452
)
Impairment of laboratory equipment

 
(1,841
)
Property and equipment, net
$
3,109

 
$
3,995

(1)
Construction in progress includes equipment received but not yet placed into service pending installation.
Intangible Assets
Intangible assets consisted of the following (in thousands): 
 
December 31, 2015
 
December 31, 2014
 
 
 
Gross
Carrying
Amount
 
Accumulated
Amortization
 
Net
Carrying
Amount
 
Gross
Carrying
Amount
 
Accumulated
Amortization
 
Net
Carrying
Amount
 
Weighted-
Average
Amortization
Period
 
 
 
 
 
 
 
 
 
(in years)
Customer relationships (1)
$

 
$

 
$

 
$
3,098

 
$
(3,098
)
 
$

 
5
Developed and core technology
1,534

 
(1,534
)
 

 
1,534

 
(1,534
)
 

 
5
Maxygen intellectual property
20,244

 
(17,432
)
 
2,812

 
20,244

 
(14,058
)
 
6,186

 
6
Total
$
21,778

 
$
(18,966
)
 
$
2,812

 
$
24,876

 
$
(18,690
)
 
$
6,186

 
6

(1)
This fully amortized asset has been retired as of December 31, 2015.
The estimated future amortization expense to be charged to research and development through the year ending December 31, 2016 is as follows (in thousands):
Year ending December 31:
Total
2016
$
2,812

Total
$
2,812


Goodwill
There were no changes in the carrying value of goodwill of $3.2 million during 2015 and 2014.
Other Accrued Liabilities
Other accrued liabilities consisted of the following (in thousands): 
 
December 31,
 
2015
 
2014
Accrued purchase (1)
$
430

 
$
612

Accrued professional and outside service fees
498

 
521

Accrued taxes
31

 
275

Deferred rent
143

 
61

Lease incentive obligation
425

 
425

Other
486

 
725

Total
$
2,013

 
$
2,619

(1)
Amount represents products and services received but have not been billed as of December 31, 2015 and 2014.